Company
Cyrus Bio
Cures by Design
Also known as Cyrus
- Status
- Operatingas of 2026-09-23
- Business model
- B2B
- Customers
- biotech/pharma companies
- Legal name
- Cyrus Biotechnology, Inc.
- cyrusbio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Cyrus Bio is a computationally-driven discovery company focused on naturally existing proteins that show the potential to be turned into superior therapeutics using computational modeling and deep mutagenesis.
Funding snapshot
- Total raised
- $37.8MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $1.5M2025-07-01
Funding rounds
- Round, 2025
- $1.5M2025-07-01, SEC form D sold, 17 investors
- Round, 2024
- $3.2M2024-10-29, SEC form D sold, 27 investors
- Round, 2024
- $2.7M2024-02-27, SEC form D sold, 33 investors
- Round, 2021
- $18.4M2021-06-22, SEC form D sold, 35 investors
- Round, 2020
- $1.1M2020-09-04, SEC form D sold, 19 investors
- Round, 2017
- $8M2017-07-13, SEC form D sold, 18 investors
- Round, 2017
- $1M2017-02-13, SEC form D sold, 13 investors
- Round, 2016
- $490K2016-11-07, SEC form D sold, 14 investors
- Round, 2016
- $535K2016-03-23, SEC form D sold, 14 investors
- Round, 2015
- $850K2015-04-22, SEC form D sold, 12 investors
Loading relationship preview